Global EditionASIA 中文雙語Fran?ais
    World
    Home / World / Americas

    Johnson & Johnson pauses COVID-19 vaccine trial over patient illness

    Xinhua | Updated: 2020-10-13 14:04
    Share
    Share - WeChat

    WASHINGTON - US pharmaceutical company Johnson & Johnson said Monday it had paused its COVID-19 vaccine trial because one of its participants had become sick.

    "We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant," the company said in a statement.

    The patient's condition was being reviewed and evaluated by the ENSEMBLE independent Data Safety Monitoring Board as well as internal clinical and safety physicians, it said.

    There are prespecified guidelines for all clinical studies, said the company. "These ensure studies may be paused if an unexpected serious adverse event (SAE) that might be related to a vaccine or study drug is reported, so there can be a careful review of all of the medical information before deciding whether to restart the study."

    Johnson & Johnson said SAEs are not uncommon in clinical trials, and the number of SAEs can reasonably be expected to increase in trials involving large numbers of participants.

    As many trials are placebo-controlled, it is not always immediately apparent whether a participant received a study treatment or a placebo, according to the company.

    The phase 3 clinical trial of Johnson & Johnson's COVID-19 vaccine started on Sept 23. The trial is designed to evaluate if the vaccine candidate could prevent symptomatic COVID-19 after a single dose regimen.

    Up to 60,000 volunteers are scheduled to be enrolled in the trial at up to nearly 215 clinical research sites in the United States and internationally.

    It is the fourth large-scale phase 3 clinical trials for a COVID-19 vaccine in the United States. The other three trials are for vaccine candidate AZD1222, co-invented by the University of Oxford and its spin-out company Vaccitech; vaccine candidate mRNA-1273, developed by the US National Institute of Allergy and Infectious Diseases and American biotechnology company Moderna; and vaccine candidate BNT162b2, developed by American biopharmaceutical company Pfizer and German company BioNTech.

    Johnson & Johnson's vaccine wing Janssen is responsible for developing the shot. While the other vaccine candidates require two doses, the Janssen vaccine candidate will be studied as a single-dose vaccine. It is a recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike protein in cells.

    Most Viewed in 24 Hours
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    亚洲综合av永久无码精品一区二区| 人妻少妇偷人精品无码| 国产成人无码综合亚洲日韩| 最近中文国语字幕在线播放视频 | 亚洲中文字幕无码爆乳AV| 无码国内精品人妻少妇| 中文字幕精品亚洲无线码一区应用| 亚洲中文字幕伊人久久无码| 秋霞鲁丝片Av无码少妇| 中文无码久久精品| 中文字幕在线播放| 欧美日韩亚洲中文字幕二区| 熟妇人妻无码中文字幕 | 国产精品 中文字幕 亚洲 欧美| 无码AV片在线观看免费| 亚洲熟妇无码八AV在线播放| 亚洲欧美精品一区久久中文字幕| 久久婷婷综合中文字幕| 中文午夜乱理片无码| 永久免费无码网站在线观看个| 国产V亚洲V天堂A无码| 免费无码又爽又刺激高潮视频| 中文字幕人妻无码系列第三区| 制服中文字幕一区二区| 日韩乱码人妻无码中文视频| 精品久久久久久久久中文字幕| 中文字字幕在线一本通| 最近的中文字幕在线看视频| 一级电影在线播放无码| 亚洲精品一级无码鲁丝片| 亚洲精品欧美精品中文字幕 | 一本一道AV无码中文字幕| 亚洲精品无码av天堂| 无码专区6080yy国产电影| 无码日韩人妻AV一区二区三区| 亚洲精品无码日韩国产不卡?V| 中文字幕人妻丝袜乱一区三区| 精品久久久久中文字幕日本| 天堂最新版中文网| 最近2019中文字幕一页二页| 国产成人亚洲综合无码|